Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

NCT01439282 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Estrogen Receptor Positive Tumor
Breast Cancer

Interventions

DRUG: eribulin mesylate
DRUG: capecitabine

Sponsor

Eisai Inc.